Abbott (ABT): Contrarian sees healthy gains

{ Posted on Jan 30 2009 by Steven Halpern }
Categories : All, BloggingStocks

Filed under: , ,

"I think 2009 will be a very tough year for the economy but an exceptional year for stocks," says Alexander Green of The Oxford Club. Here, he looks at Abbott Laboratories (NYSE: ABT).

"The company has been around for more than 120 years. It currently operates in more than 130 countries, selling hundreds of products, including Ultane (an inhaled anesthetic), the anti-infective Biaxin XL, and TriCor and Niaspan to manage cholesterol.

"However, Abbott's biggest growth driver is Humira, a blockbuster drug that targets autoimmune disorders. The drug has received FDA approval to treat a number of diseases, including rheumatoid arthritis, psoriasis and Crohn's disease.

Continue reading Abbott (ABT): Contrarian sees healthy gains

Abbott (ABT): Contrarian sees healthy gains originally appeared on BloggingStocks on Fri, 30 Jan 2009 12:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments

Add to digg Add to del.icio.us Add to Google Add to StumbleUpon Add to Facebook Add to Reddit Add to Technorati
This entry was posted on Friday, January 30th, 2009 at 1:30 pm and is filed under All, BloggingStocks. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.

Post a Comment